Browse Catalog →

Science Library · Actin & tissue repair

TB-500 the science.

TB-500 is a synthetic peptide based on the active region of thymosin β4, a small protein found in nearly all human cells that helps organize the actin cytoskeleton. In preclinical research it is studied for cell migration, blood-vessel formation, and tissue repair. The findings below are from cell and animal models.

View the TB-500 product page →

Tβ4
Parent protein
G-actin
Binding target
Preclinical
Evidence stage
Cardiac & wound
Models studied
TB-500 research vial

How it works

Mechanism at a glance

Compound
TB-500
Action
Binds G-actin
Effect
Cell migration & angiogenesis
Studied for
Tissue repair

Evidence to date

Evidence to date: animal and cell models. No human trials.

What it is

Thymosin β4 is a 43-amino-acid protein and one of the most abundant actin-binding molecules in the body, where it acts as the main intracellular G-actin sequestering protein — a regulator of cell shape, motility, and migration. TB-500 corresponds to the peptide’s active actin-binding region, centered on the LKKTETQ motif, and is produced synthetically as a research peptide.

Pathways under study

Peer-reviewed research has identified several mechanisms:

  • G-actin sequestration — regulation of the actin cytoskeleton, driving cell migration into wound sites.
  • Angiogenesis — promotion of new blood-vessel formation.
  • Matrix & inflammation — upregulation of MMP-2 and modulation of inflammatory signaling.

What research has explored

Thymosin β4 / TB-500 is one of the more extensively studied tissue-repair peptides in preclinical research:

  • Cardiac models (2004). A landmark study reported that thymosin β4 promoted cardiac-cell migration, survival, and repair in animal models, acting through integrin-linked kinase.
  • Wound, corneal & musculoskeletal repair. A 2005 review summarized thymosin β4’s role as an actin-sequestering protein that “moonlights” to assist repair across multiple tissue types.

These are observations in animals and cells; human therapeutic use is not established.

Current state of the evidence

The TB-500 / thymosin β4 evidence base is preclinical. No human safety, dosing, or efficacy is established here, and TB-500 is supplied strictly as a research material for laboratory investigation.

Compound Snapshot

At a glance

Identity

What is TB-500?

Type
Synthetic peptide (thymosin β4 fragment)
Parent protein
Thymosin β4 (43 amino acids)
Active motif
LKKTETQ (actin-binding region)
Primary activity
G-actin sequestration
Research family
Tissue repair
Use classification
Research Use Only
PubChem Database

Evidence base

Research maturity

Preclinical Animal & in vitro No human trials
Maturity Preclinical Animal and cell-model literature across cardiac, corneal, and musculoskeletal repair.
Translation Not established in humans Preclinical findings do not establish human safety, dosing, or benefit.

Sources & References

Peer-reviewed research and database records

Nature / PubMed

Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

2004 · PMID 15565145 · DOI 10.1038/nature03000 View Source

Trends in Molecular Medicine / PubMed

Thymosin β4: actin-sequestering protein moonlights to repair injured tissues

2005 · PMID 16099219 · DOI 10.1016/j.molmed.2005.07.004 View Source

PubChem

Thymosin β4 / TB-500 compound search

NIH PubChem lookup for molecular identity and structure records. View Source

PubMed

TB-500 / thymosin β4 literature search

NCBI PubMed index for primary papers and reviews. View Source

For research use only. Not for human or veterinary use. These products have not been evaluated by the FDA. Nothing on this page is medical advice or a therapeutic claim.

Catalog

Explore TB-500.

View product →